A group of generic drug manufacturers has asked the US Supreme Court to allow a ruling that grants them permission to market a version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).
The UK High Court has invalidated two patents covering Roche’s breast cancer drug Herceptin (trastuzumab) after a challenge by generic drug maker Hospira.
Law firm Mintz Levin Cohn Ferris Glovsky and Popeo PC has added three partners to its IP team.
US law firm O’Melveny & Myers LLP has hired Lisa Barons Pensabene, Marc Pensabene, and Filko Prugo at its New York office.
Dublin-based Mallinckrodt Pharmaceuticals has announced it will buy US biopharmaceutical company Questcor Pharmaceuticals for $5.6 billion.
OxyContin (oxycodone hydrochloride) maker Purdue Pharma has filed suit against Teva to stop the generic drug maker trying to litigate claims to a patent for which it had filed a Paragraph III certification.
Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone.
Mumbai-based Sun Pharmaceutical Industries is buying Indian rival Ranbaxy Laboratories in a merger worth $3.2 billion, the companies have confirmed.
Generic drug maker Prasco Laboratories has agreed to market and distribute an authorised generic version of Eli Lilly’s Evista (raloxifene hydrochloride) in the US.
Cooley LLP has recruited Ivor Elrifi and Heidi Erlacher to the patent counselling team serving the life sciences and technology sectors.